Development of novel vaccine against tuberculosis using recombinant BCG expressing SOCS1 antagonist

• Project/Area Number: 22890255
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Single-year Grants
• Research Field: Immunology
• Research Institution: 独立行政法人医薬基盤研究所
• Principal Investigator: WATANABE Kenta 独立行政法人医薬基盤研究所, 霊長類医科学研究センター, 研究員 (20582208)
• Co-Investigator(Renkei-kenkyūsha): MATSUO Kazuhiro 日本BCG研究所, 研究開発部, 研究開発部長 (70521095)
• Project Period (FY): 2010 – 2011
• Project Status: Completed (Fiscal Year 2011)
• Budget Amount: ¥3,016,000 (Direct Cost: ¥2,320,000、Indirect Cost: ¥696,000); Fiscal Year 2011: ¥1,443,000 (Direct Cost: ¥1,110,000、Indirect Cost: ¥333,000); Fiscal Year 2010: ¥1,573,000 (Direct Cost: ¥1,210,000、Indirect Cost: ¥363,000)
• Keywords: 結核ワクチン / BCG / SOCS1

Research Abstract

I developed novel vaccine against tuberculosis using recombinant BCG expressing dominant negative of SOCS1(rSOCS-DN/BCG), and evaluated the effectiveness in mice. rSOCS-DN/BCG immunization elicited Mycobacterium antigen specific immune responses. Furthermore the immunization with rSOCS-DN/BCG showed significant protection against tuberculosis in mice. These results indicated further evidences for the possibility of rSOCS-DN/BCG as a novel vaccine against tuberculosis.